Companies › Incyte Biosciences International Sàrl
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 1 | Acute Myeloid Leukemia | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03934372 | Ponatinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Feb 2028 |
Cash of $3.3bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.